Epigenomics AG Receives Allowance for Key Technology Patent in Japan
Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products
Epigenomics AG announced that it received a Notice of Allowance by the Japanese Patent Office stating that they intend to grant a patent for Epigenomics' HeavyMethyl(TM) technology. This notification is equivalent to a "Rule 71(3) notification" by the European Patent Office. Patent application 2002-571930 titled "Highly sensitive method for the detection of cytosine methylation patterns.", claims very broadly a method for the detection of DNA methylation by means of amplification that employs blockers to prevent the amplification of background DNA while not affecting the amplification of target DNA. The patent is already granted in the US, Europe, China, Russia, Australia, South Korea, and New Zealand.
The HeavyMethyl(TM) technology allows the specific and highly sensitive detection of methylated DNA in large background of unmethylated DNA using real-time PCR, the current industry technology standard in molecular diagnostics. The technology is currently used in Epigenomics' own in vitro diagnostic products for the early detection and diagnosis of cancer as well as in products of Epigenomics' biomarker and technology licensees.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.